

# Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis

*Jingshu Meng<sup>†1</sup>, Yan Li<sup>†1</sup>, Chao Wan<sup>†1</sup>, Yajie Sun<sup>†</sup>, Xiaomeng Dai<sup>†</sup>, Jing Huang<sup>†</sup>, Yan Hu<sup>†</sup>, Yanan Gao<sup>†</sup>, Bian Wu<sup>†</sup>, Zhanjie Zhang<sup>†</sup>, Ke Jiang<sup>#</sup>, Shuangbing Xu<sup>†</sup>, Jonathan F. Lovell<sup>‡</sup>, Yu Hu<sup>^</sup>, Gang Wu<sup>†</sup>, Honglin Jin<sup>†\*</sup>, and Kunyu Yang<sup>†\*</sup>*

<sup>†</sup>Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

<sup>#</sup>Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

<sup>^</sup>Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

<sup>‡</sup>Department of Chemical and Biological Engineering, University at Buffalo, State University of New York. Buffalo, New York 14260, USA

<sup>1</sup> These authors contributed equally to this work.

\*Correspondence: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Fax: +86-27-65650733; Tel:

+86-27-85873100.


Email: Honglin Jin, [jin@hust.edu.cn](mailto:jin@hust.edu.cn); Kunyu Yang, [yangkuny@hust.edu.cn](mailto:yangkuny@hust.edu.cn);

### Conflict of interest


The authors have declared that no conflict of interest exists.

**Keywords:** fibroblasts, CAFs, senescence, radiosensitivity, pulmonary fibrosis, FOXO4-DRI, NSCLC

### Supplementary information




**Figure S1.** Representative images of primary CAFs obtained from surgical specimens detected by immunofluorescence staining. Scale bar, 100  $\mu$ m.




**Figure S2. IR-induced CAFs senescence. (A)** Cell proliferation curves of CAFs with or without 10-Gy IR.

The indicated results represent the means  $\pm$  SEM of three independent experiments, analyzed by two-way ANOVA. **(B)** mRNA expression of SASP in CAFs 10 days after 10-Gy IR. The indicated results represent the means  $\pm$  SEM of three independent experiments, analyzed by Student's t test. **(C)** Positive rate of SA- $\beta$ -Gal staining in CAFs 10 days after 10-Gy IR. The indicated results represent the means  $\pm$  SEM of three independent experiments, analyzed by two-way ANOVA. **(D)** Western blot identifying the gene expression changes of senescence-associated genes in CAFs 10 days after IR. \*\*\*  $P < 0.001$ .




**Figure S3. SL-CAFs promote NSCLC cells Ki67 expression.** (A) Left panel, Ki67 expression of A549 and Hcc827 cells cultured with CAFs CM or SL-CAFs CAFs CM for 48 h detected by flow cytometry. Right panel, quantitative mean fluorescence intensity (MFI) of Ki67 detected by flow cytometry in indicated group of A549 and Hcc827 cells. The results represent the means  $\pm$  SEM of three or four independent experiments, analyzed by one-way ANOVA. (B) Above panel, representative images of EdU staining for A549 and Hcc827 cultured with normal medium, CAFs CM, or SL-CAFs CM for 48 h. Scale bar, 50  $\mu$ m. Below panel, quantification of EdU positive A549 and Hcc827 cells detected by flow cytometry. The indicated results represent the means  $\pm$  SEM of three microscopic fields, analyzed by one-way ANOVA. \*  $P < 0.05$ , \*\*  $P <$


0.01, \*\*\*  $P < 0.001$ . SL-CAFs, senescence-like CAFs.




**Figure S4. SL-CAFs increases the viability of NSCLC cells by reducing apoptosis after radiation.** H292, A549, Hcc827 cells cultured in normal medium, CAFs CM and SL-CAFs CM for 48 h and then irradiated by 8-Gy IR. The cell viability determined 72 h after IR and normalized to non-IR cells by CCK8 assay. The indicated results represent the means  $\pm$  SEM of three independent experiments, \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , n.s., not statistically significant analyzed by one-way ANOVA. zVAD, Z-VAD-FMK. SL-CAFs, senescence-like CAFs.




**Figure S5. NSCLC cells apoptosis rates after 8-Gy IR detected by flow cytometry.** Representative images of H292, A549 and Hcc827 cells apoptosis 72 h after 8-Gy IR detected by flow cytometry using annexin-V staining as indicated in different groups. SL-CAFs, senescence-like CAFs.



**Figure S6. SL-CAFs induce radioresistance of NSCLC cells *via* STAT3 activation.** (A-C) H292, A549 and Hcc827 cells apoptosis after 8-Gy IR detected by flow cytometry using annexin-V staining (left) and quantitative data of the apoptosis rate (right) as indicated in different groups. (D) Clonogenic survival fraction of H292, A549 and Hcc827 cells after 8-Gy IR with STAT3 inhibitor S3I-201. The indicated results represent the means  $\pm$  SEM of three independent experiments, \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , analyzed by one-way ANOVA. S3I, S3I-201. SL-CAFs, senescence-like CAFs.




**Figure S7. Western blot identifying the knockdown effect of STAT3 gene by three designed siRNA.**



**Figure S8. Reverse of A549 and Hcc827 cells radioresistance with FOXO4-DRI by targeting SL-CAFs.**




**(A)** A549 cells apoptosis after 8-Gy IR detected by flow cytometry using annexin-V staining (left) and quantitative data of the apoptosis rate (right) as indicated in different groups. **(B)** Left panel, representative images of colony formation in A549 cells cultured in different medium with or without 8-Gy IR; right panel, statistically clonogenic survival fraction of A549 cells with different treatment after 8-Gy IR determined by plate clone formation assay. **(C)** A549 cells cultured in different medium for 48 h and then irradiated by 8-Gy IR. The cell viability determined 72 h after IR by CCK8 assay and normalized to non-IR cells. **(D)** Hcc827 cells apoptosis after 8-Gy IR detected by flow cytometry using annexin-V staining (left) and quantitative data of the apoptosis rate (right) as indicated in different groups. **(E)** Left panel, representative images of colony formation in Hcc827 cells cultured in different medium with or without 8-Gy IR; right panel, statistically clonogenic survival fraction of Hcc827 cells with different treatment after 8-Gy IR determined by plate clone formation assay. **(F)** Hcc827 cells cultured in different medium for 48 h and then irradiated by 8-Gy IR. The cell viability determined 72 h after IR by CCK8 assay and normalized to non-IR cells. All the indicated results represent the means  $\pm$  SEM of three independent experiments, analyzed by one-way ANOVA. \* $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ . SL-CAFs, senescence-like CAFs. DRI-CAFs, senescence-like CAFs co-cultured with FOXO4-DRI.




**Figure S9.** (A) The photo of dissected tumors in mice subcutaneously co-injected of Hcc827 cells with CAFs or SL-CAFs. Hcc827 cells injected alone as control. (B) Left panel, representative images of cleaved caspase3 positive cells in xenograft tumors detected by immunohistochemistry staining. Scale bar, 50 $\mu$ m. Right panel, the percentage of cleaved caspase3 positive area in xenograft tumors detected by immunohistochemistry staining. Mean  $\pm$  SEM (3 microscopic fields at 400 $\times$  magnification per mice to evaluate the averaged positive area, n = 6-7 mice per group), analyzed by Student's t-test. (C) Left panel, representative images of GFP<sup>+</sup> cells in xenograft tumors detected by immunofluorescence staining. Scale bar, 50  $\mu$ m. Right panel, the percentage of GFP<sup>+</sup> cells area in xenograft tumors detected by immunofluorescence staining. Mean  $\pm$  SEM (3 microscopic fields at 400 $\times$  magnification per mice to evaluate


the averaged GFP<sup>+</sup> area, n = 2 mice per group), analyzed by Student's t-test. \* $P < 0.05$ , \*\*\*  $P < 0.001$ . SL-CAFs, senescence-like CAFs.



**Figure S10. Effect of FOXO4-DRI in improving radiosensitivity *in vivo*.** (A) Tumor growth curves for mice subcutaneously co-injected of H292 cells with SL-CAFs or CAFs. H292 cells injected alone as control. Mean  $\pm$  SEM (n = 6 mice per group), analyzed by two-way ANOVA. (B) The photo of dissected tumors in mice subcutaneously co-injected of H292 cells with CAFs or SL-CAFs and (C) quantification of tumor weights in each group. Mean  $\pm$  SEM (n = 6 mice per group), analyzed by one-way ANOVA. (D) Tumor growth curves for mice in different groups after IR. Mean  $\pm$  SEM (n = 6 mice per group), analyzed by two-way ANOVA. (E) The photo of dissected tumors and (F) quantification of tumor weights in each group after IR. Mean  $\pm$  SEM (n = 6 mice per group), analyzed by one-way ANOVA. \* $P < 0.05$ , \*\*\*  $P < 0.001$ , n.s., not statistically significant. SL-CAFs, senescence-like CAFs.



**Figure S11. Effect of FOXO4-DRI on improving radiosensitivity *in vivo*.** (A) Tumor growth curves for C57BL/6 mice subcutaneously injected of Lewis cells with different treatment. Mean  $\pm$  SEM (n = 6 mice per group), analyzed by two-way ANOVA. (B) The photo of dissected tumors and (C) quantification of tumor weights in each group. Mean  $\pm$  SEM (n = 6 mice per group), analyzed by one-way ANOVA. \*  $P < 0.05$ , \*\*\*  $P < 0.001$ , n.s., not statistically significant.



**Figure S12. Cell viability assay of HFL1 and SL-HFL1 treating with different concentrations of FOXO4-DRI for 72 h.** The indicated results represent the means  $\pm$  SEM of three independent experiments. SL-HFL1, senescence-like HFL1.

**Table S1. Information of patients whose clinical samples were used for isolation of CAFs.**

Patients ID	Gender	Age (y)	Pathological type	Stage	TNM
NSCLC001	M	77	LUAD	III A	T <sub>1b</sub> N <sub>2</sub> M <sub>0</sub>
NSCLC002	M	70	LUAD	I B	T <sub>2a</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC003	M	71	LUSC	II B	T <sub>3</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC004	F	75	LUAD	III A	T <sub>1a</sub> N <sub>2</sub> M <sub>0</sub>
NSCLC005	M	58	LUAD	I A	T <sub>1b</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC006	F	48	LUAD	III A	T <sub>1c</sub> N <sub>2</sub> M <sub>0</sub>
NSCLC007	M	65	LUAD	I A	T <sub>1b</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC008	F	56	LUAD	III A	T <sub>4</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC009	F	55	LUAD	III A	T <sub>2a</sub> N <sub>2</sub> M <sub>0</sub>
NSCLC010	M	50	LUSC	II B	T <sub>2b</sub> N <sub>1</sub> M <sub>0</sub>
NSCLC011	F	58	LUAD	I A	T <sub>1c</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC012	M	65	LUAD	I B	T <sub>2a</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC013	M	64	LUSC	II A	T <sub>2b</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC014	M	60	LUSC	II A	T <sub>2a</sub> N <sub>1</sub> M <sub>0</sub>
NSCLC015	M	62	LUAD	III A	T <sub>2a</sub> N <sub>2</sub> M <sub>0</sub>
NSCLC016	F	63	LUAD	I A	T <sub>1c</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC017	M	54	LUAD	I A	T <sub>1c</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC018	M	67	LUAD	I A	T <sub>1b</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC019	M	41	LUAD	III B	T <sub>4</sub> N <sub>2</sub> M <sub>0</sub>
NSCLC020	M	57	LUAD	I A	T <sub>1c</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC021	M	67	LUSC	II A	T <sub>2b</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC022	F	56	LUAD	I A	T <sub>1c</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC023	M	61	LUAD	I B	T <sub>2a</sub> N <sub>0</sub> M <sub>0</sub>
NSCLC024	F	61	LUAD	III A	T <sub>2a</sub> N <sub>2</sub> M <sub>0</sub>

NSCLC = non-small cell lung cancer, M = male, F = female, LUAD = lung adenocarcinoma, LUSC = lung squamous cell carcinoma, T = tumor, N = node, M = metastasis.

**Table S2. Plating efficiencies of NSCLC cells in plate clone formation assay.**

	H292			A549			Hcc827		
	Ctrl	CAFs CM	SL-CAFs CM	Ctrl	CAFs CM	SL-CAFs CM	Ctrl	CAFs CM	SL-CAFs CM
0 Gy	0.1853	0.1853	0.1907	0.3373	0.3433	0.3327	0.1900	0.1893	0.1907
2 Gy	0.0623	0.0757	0.0913	0.1183	0.1353	0.1320	0.0530	0.0653	0.0660
4 Gy	0.0255	0.0408	0.0540	0.0438	0.0570	0.0645	0.0093	0.0173	0.0262
6 Gy	0.0073	0.0163	0.0318	0.0107	0.0145	0.0213	0.0015	0.0033	0.0067
8 Gy	0.0009	0.0028	0.0086	0.0018	0.0032	0.0074	0.0003	0.0009	0.0023

**Table S3. Sequences of primer used in RT-qPCR analysis.**

Gene name	Forward primer	Reverse primer
<i>TP53</i>	GAGTCAACGGATTTGGTCGT	GACAAGCTTCCCGTTCTCAG
<i>CDKN1A</i>	GACAGCAGAGGAAGACCATGTGGAC	GAGTGGTAGAAATCTGTCATGCTG
<i>CDKN2A</i>	CCAACGCACCGAATAGTTACG	GCGCTGCCCATCATCATG
<i>IL1A</i>	AGATGCCTGAGATACCCAAAACC	CCAAGCACACCCAGTAGTCT
<i>IL1B</i>	ATGATGGCTTATTACAGTGGCAA	GTCGGAGATTCGTAGCTGGA
<i>IL6</i>	CGGTCCAGTTGCCTTCTCCC	GAGTGGCTGTCTGTGTGGGG
<i>IL8</i>	CTCTTGGCAGCCTTCCTGATT	TATGCACTGACATCTAAGTTCTTTAGCA
<i>βGal</i>	TTAGGATGTGCATTTTCACCTGA	CTTTGGCACTGCAGGGATG
<i>TGFB1</i>	CAATTCCTGGCGATACCTCAG	GCACAACCTCCGGTGACATCAA
<i>FGF7</i>	CTGAGGATCGATAAAAAGAGGCAA	ATTCTTCATCTCTTGGGTCCCTT
<i>HGF</i>	GTTCTGGTCGTGGATGTGC	TCGGACAAAAATACCAGGACG
<i>MMP1</i>	GGGCTTGAAGCTGCTTACGA	TGTCCCTGAACAGCCCAGTAC
<i>MMP3</i>	AGAGGTGACTCCACTCACAT	GGTCTGTGAGTGAGTGATAG

**Table S4. Sequences of three designed siRNA targeting STAT3.**

SiRNA	Sense (5'-3')	Anti-sense (3'-5')
#1	CCACUUUGGUGUUUCAUAATT	UUAUGAAACACCAAAGUGGTT
#2	GCAACAGAUUGCCUGCAUUTT	AAUGCAGGCAAUCUGUUGCTT
#3	CCCGUCAACAAAUUAAGAATT	UUCUAAAUUGUUGACGGGTT